Odyssea Pharma

Odysea Pharma is a pharmaceutical development and production centre part of Abbvie group. Odyssea is designated as one of the group's Centre of Excellence for women’s health delivering product development, GMP manufacturing of Levosert™ hormonal intra-uterine device and quality & regulatory expertise from a custom-designed facility located in Liège, Belgium. NDA approved in 2014, Odyssea Pharma is developing industrial activities with a dedicated production area to Levosert™ hormonal intra-uterine device (IUD) a flexible frame which consistently releases small quantities of levonorgestrel in the uterine cavity. With Sponsor Medicines 360 our two handed inserter Levosert is produced at industrial scale for Europe and US. Global in reach. Specialised in focus. On March 17th, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team around the world What are we - Part of the Abbvie Group today Odyssea is - A full GMP Manufacturing production (including primary and secondary packaging)- A full analytical / QC support: method development, method validation, routine tests, stability studies- A full QA support compliant with European guidelines- CE Mark and NDA approved - A company people oriented, were it is nice to have a job